The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...

In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...

Ladies and gentlemen, thank you for standing by, and welcome to the COMPASS Pathways Limited fourth quarter 2024 investor call. [Operator instructions] I will now hand today's call over to Steve ...

2025 Financial Guidance: Expected net cash used in operations to be within the range of $120 million to $145 million. Compass Pathways PLC (NASDAQ:CMPS) has secured financing that positions the ...